Expert Opinion on Pharmacotherapy最新文献

Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies. 结核病和糖尿病之间的临床、代谢和免疫相互作用：治疗的意义和机会。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-26 DOI: 10.1080/14656566.2025.2508904

Itai M Magodoro, Leigh A Kotze, Cari J Stek, Alexander West, Andrea Le Roux, Nadja Sobratee, Arshad Taliep, Yohhei Hamada, Joel A Dave, Molebogeng X Rangaka, Suraj P Parihar, Robert J Wilkinson

{"title":"Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies.","authors":"Itai M Magodoro, Leigh A Kotze, Cari J Stek, Alexander West, Andrea Le Roux, Nadja Sobratee, Arshad Taliep, Yohhei Hamada, Joel A Dave, Molebogeng X Rangaka, Suraj P Parihar, Robert J Wilkinson","doi":"10.1080/14656566.2025.2508904","DOIUrl":"10.1080/14656566.2025.2508904","url":null,"abstract":"Introduction: Tuberculosis (TB) remains a major infectious threat to global health, while type 2 diabetes mellitus (diabetes) has reached epidemic proportions in many regions of the world. In low- and middle-income countries (LMIC) and among indigenous and minority communities in high-income settings (HIC), these diseases also increasingly overlap, posing new clinical and therapeutic challenges.Areas covered: We searched PubMed/CINAHL/Web of Science/Scopus, Google Scholar up to 30 November 2024. Meanwhile, the Immuno-metabolic parallels between TB and Diabetes are underappreciated. Improved understanding of mechanisms may pave the way for novel therapeutic strategies, for example, using antidiabetic medications as adjuvant host-directed therapies (HDT) in active TB. We review the epidemiology of TB, diabetes and their combined comorbidity, their immune and metabolic mechanisms and clinical relevance, as well as potential opportunities for general and targeted therapeutic intervention.Expert opinion: Immunometabolic interaction between diabetes and tuberculosis is bidirectional. Underlying this interaction are shared inflammatory mechanisms. It follows that treatments for diabetes and its complication may be beneficial in tuberculosis and that the treatment of both active and latent tuberculosis may improve glycemic control. These interactions are amenable to investigation in experimental models, in human experimental medicine studies and in clinical trials.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder. 患有自闭症、注意力缺陷和多动障碍的儿童和青少年失眠的药物管理。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-26 DOI: 10.1080/14656566.2025.2508277

Valeria Mammarella, Ludovico Randazzo, Sara Romano, Maria Breda, Oliviero Bruni

{"title":"Pharmacological management for insomnia in children and adolescents with autism and attention deficit and hyperactivity disorder.","authors":"Valeria Mammarella, Ludovico Randazzo, Sara Romano, Maria Breda, Oliviero Bruni","doi":"10.1080/14656566.2025.2508277","DOIUrl":"10.1080/14656566.2025.2508277","url":null,"abstract":"Introduction: Insomnia is common in children and adolescents with autism spectrum disorder (ASD) and/or attention deficit and hyperactivity disorder (ADHD), with significant implications for quality of life and prognosis. Although non-pharmacological interventions represent the first-line approach, they are not always effective. Therefore, it is important to determine when a pharmacological treatment can be indicated and which compound to prefer based on evidence of efficacy and safety.Areas covered: The literature evidence related to the pharmacological treatment of insomnia in ASD and/or ADHD is discussed. We present data on drugs and supplements used and considerations about the choice of starting a pharmacological therapy, suggesting clinical advice that may guide clinicians.Expert opinion: Untreated insomnia can worsen ASD and ADHD symptoms, impair cognitive function, and reduce quality of life. Targeted interventions are essential. Behavioral strategies, with or without melatonin, are recommended after evaluating comorbidities and medications. Off-label treatments for children with ASD include antihistamines, alpha-adrenergics, trazodone, antidepressants, antipsychotics, anticonvulsants, and hypnotics. For ADHD, options include iron supplementation for restlessness and low ferritin levels, and alpha2-adrenergics like guanfacine and clonidine for their sedative effects.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-20"},"PeriodicalIF":2.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Approved medications for opioid use disorder : current update. 阿片类药物使用障碍的批准药物：最新更新。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-21 DOI: 10.1080/14656566.2025.2507124

Michael Soyka

{"title":"Approved medications for opioid use disorder : current update.","authors":"Michael Soyka","doi":"10.1080/14656566.2025.2507124","DOIUrl":"10.1080/14656566.2025.2507124","url":null,"abstract":"Introduction: Opioid use disorder (OUD) is recognized as a chronic, relapsing disorder with a high mortality and psychiatric and somatic comorbidity.Areas covered: Existing guidelines and meta-analyses on pharmacotherapy of opioid use disorder were reviewed. Opioid maintenance treatment (OMT) is the generally accepted first line treatment in OUD with oral methadone and buprenorphine being the gold standard. In recent years a number of novel opioids have been introduced into clinical practice including depot formulations of buprenorphine, retarded morphine and heroin (diacetylmorphine). The review refers to the different drugs available and gives an overview on clinical use, side effects, and efficacy in certain subgroups.Expert opinion: OMT is a success story with emerging new pharmacological options available. While oral methadone or buprenorphine still are the most suitable medications for many patients, depot formulations of buprenorphine may improve adherence and facilitate clinical management of many patients. Diacetylmorphine and retarded morphine are second line medications for treatment refractory patients. Future research may focus on responder characteristics for certain medications and efficacy in special subgroups as well as interaction of psychosocial and pharmacological treatments.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-15"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy. 评估化疗引起的周围神经病变的MiroCIP研究的亚组分析：症状概况，严重程度和镇痛效果取决于化疗类型。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-19 DOI: 10.1080/14656566.2025.2499665

Sonoko Misawa, Takahiro Kogawa, Yoichi Naito, Takuji Suzuki, Mamoru Takada, Tadamichi Denda, Aoi Hino, Tomoki Suichi, Sho Kodama, Arisa Miyoshi, Kazuhito Shiosakai, Satoshi Kuwabara

{"title":"A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy.","authors":"Sonoko Misawa, Takahiro Kogawa, Yoichi Naito, Takuji Suzuki, Mamoru Takada, Tadamichi Denda, Aoi Hino, Tomoki Suichi, Sho Kodama, Arisa Miyoshi, Kazuhito Shiosakai, Satoshi Kuwabara","doi":"10.1080/14656566.2025.2499665","DOIUrl":"10.1080/14656566.2025.2499665","url":null,"abstract":"Background: The multicenter, prospective MiroCIP observational study investigated the incidence, risk factors, and outcomes of chemotherapy-induced peripheral neuropathy (CIPN) by oxaliplatin- and taxane-based chemotherapies but did not examine their differences in detail. This post hoc subanalysis explored the differences between oxaliplatin- and taxane-based chemotherapy, in terms of CIPN symptom profile, severity, and response to analgesics.Research design and methods: Patients with colorectal, gastric, non-small cell lung, or breast cancer, scheduled to receive oxaliplatin- or taxane-based chemotherapy, were followed for 12 months to assess the severity of sensory CIPN, by the Common Terminology Criteria for Adverse Events, and associated subjective and objective symptoms.Results: Overall, 91 patients received oxaliplatin and 131 received a taxane. At 12 months, CIPN prevalence was 74.6% with oxaliplatin and 55.2% with a taxane. Grade ≥ 2 CIPN peaked at 9 months with oxaliplatin and at 3 months with a taxane, with most symptom scores following a similar trajectory. Analgesic efficacy differed between subgroups, providing marked reductions in pain/tingling scores in the taxane group but minimal effect in the oxaliplatin group.Conclusions: CIPN course and symptoms vary with oxaliplatin- or taxane-based chemotherapy. Effective management should be tailored to the type of chemotherapy: oxaliplatin-treated patients may benefit from continuous monitoring of CIPN symptoms, whereas it may be beneficial for taxane-treated patients to receive appropriate analgesics at CIPN onset.Trial registration: Japan Registry of Clinical Trials jRCTs031210101.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy. 是时候重新考虑高血压左室肥厚患者抗高血压药物的选择方法了。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-19 DOI: 10.1080/14656566.2025.2508282

Goran Koraćević, Milovan Stojanović, Marija Zdravković, Ruzica Janković Tomasević, Snežana Ćirić Zdravković, Nenad Božinović, Predrag Cvetković, Milorad Pavlović, Dimitrije Pavlović

{"title":"Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy.","authors":"Goran Koraćević, Milovan Stojanović, Marija Zdravković, Ruzica Janković Tomasević, Snežana Ćirić Zdravković, Nenad Božinović, Predrag Cvetković, Milorad Pavlović, Dimitrije Pavlović","doi":"10.1080/14656566.2025.2508282","DOIUrl":"10.1080/14656566.2025.2508282","url":null,"abstract":"Introduction: Hypertensive left ventricular hypertrophy (HTN LVH) is a highly prevalent high-risk condition, and the recommendations for HTN LVH treatment are essentially unchanged for several decades.Areas covered: The current therapeutic approach to HTN LVH is to choose antihypertensive drugs according to their ability to reverse left ventricular (LV) remodeling. On the other hand, for the majority arterial hypertension (HTN) patients we should start treatment with a combination of different antihypertensive drugs. Therefore, the goal of antihypertensive treatment of HTN LVH should be adapted to the current recommendation in other parts of guidelines. The recommendation we need is not only which individual drug, but rather which combination of two antihypertensive agents is optimal for reversed LV remodeling.Expert opinion: In this paper, we pointed out that treatment recommendation for HTN LVH can be updated in a similar way as therapy for the whole HTN population - by recommending a combination of two or three antihypertensives in a single pill. Clinicians should be directly advised what is the first- and what the second-line combination of antihypertensives for HTN LVH in evidence-based medicine. Therefore, we suggest that combination treatment should be studied, compared and then recommended also for very prevalent higher-risk HTN LVH patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selecting optimal therapy for Langerhans cell histiocytosis: current state and future directions. 选择最佳治疗朗格汉斯组织细胞增多症：现状和未来的方向。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-18 DOI: 10.1080/14656566.2025.2508276

Moza Hamoud, Ruba Alchaikh Hassan, Constantin A Dasanu

引用次数: 0

Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder. 阿片类药物使用障碍患者的药物和行为疼痛治疗策略。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-17 DOI: 10.1080/14656566.2025.2506688

Victoria Ameral, Thomas R Hickey, Erin Dawna Reilly, Jessica A Patterson, Mehmet Sofuoglu

{"title":"Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder.","authors":"Victoria Ameral, Thomas R Hickey, Erin Dawna Reilly, Jessica A Patterson, Mehmet Sofuoglu","doi":"10.1080/14656566.2025.2506688","DOIUrl":"10.1080/14656566.2025.2506688","url":null,"abstract":"Introduction: A critical challenge in providing effective medical care for individuals in opioid agonist treatment (OAT) for opioid use disorder is the effective management of acute and chronic pain. While pain commonly co-occurs with opioid use disorder, there is limited research to guide effective management of pain in this population.Areas covered: We first provide an overview of the etiology and treatment of acute and chronic pain, highlighting areas of complexity for patients receiving OAT. We then describe the search strategy, which involved a date-inclusive search for relevant terms in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. After summarizing the results of this search on the evidence for pharmacological and behavioral treatments of acute and chronic pain for individuals on OAT, we conclude with a discussion of these findings and a summarized expert opinion on the state of the evidence.Expert opinion: The evidence suggests that while research on effective treatment of acute and chronic pain in individuals in OAT is limited, promising work is ongoing to translate existing treatments, particularly behavioral treatments for chronic pain, to support this population. However, further research is warranted, particularly regarding pharmacological options.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need. 选择合适的治疗皮肤t细胞淋巴瘤（ctcl）：最近的进展和未满足的需求。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-14 DOI: 10.1080/14656566.2025.2503850

Sayan Poursadrolah, Ruba Alchaikh Hassan, Ion Codreanu, Constantin A Dasanu

引用次数: 0

The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents. 2型糖尿病心血管优化的当代景观：克服循证使用新型降糖药的障碍

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-13 DOI: 10.1080/14656566.2025.2504702

Kareem Malas, Salman Kazmi, Yu Mi Kang, Darren K McGuire

{"title":"The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents.","authors":"Kareem Malas, Salman Kazmi, Yu Mi Kang, Darren K McGuire","doi":"10.1080/14656566.2025.2504702","DOIUrl":"https://doi.org/10.1080/14656566.2025.2504702","url":null,"abstract":"Introduction: Cardiometabolic diseases, particularly type 2 diabetes (T2D) and cardiovascular disease (CVD), represent leading global health challenges with rising incidence and prevalence. Despite strong evidence supporting the benefits of sodium-glucose cotransporter inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in managing CVD risk in T2D, these therapies remain underutilized.Areas covered: This review discusses the present state of SGLT2i and GLP-1 RA usage, emphasizing barriers to their adoption, including clinical inertia, high costs, and misconceptions about injectable therapies. The literature search was conducted using PubMed, UpToDate, major society journals, and clinical guidelines. Information was gathered from cohort studies, survey reports, randomized controlled trials, and meta-analyses that examine the effectiveness and challenges surrounding these treatments.Expert opinion: Addressing the underuse of SGLT2i and GLP-1 RA requires a multifaceted approach. Key strategies include improving prescriber awareness, reducing out-of-pocket costs, fostering interdisciplinary collaboration, and leveraging digital health tools. Implementation science has shown promise in enhancing therapy uptake. Future efforts must integrate these therapies into value-based care models to ensure timely, equitable access, ultimately reducing cardiovascular (CV) morbidity and mortality in high-risk T2D populations.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in understanding migraine for the development of novel pharmacotherapies: the use of human provocation migraine models. 了解偏头痛的新药物治疗进展：人类诱发偏头痛模型的使用。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-05-12 DOI: 10.1080/14656566.2025.2505231

Nazia Karsan, Sina Marzoughi, Peter J Goadsby

{"title":"Advances in understanding migraine for the development of novel pharmacotherapies: the use of human provocation migraine models.","authors":"Nazia Karsan, Sina Marzoughi, Peter J Goadsby","doi":"10.1080/14656566.2025.2505231","DOIUrl":"https://doi.org/10.1080/14656566.2025.2505231","url":null,"abstract":"Introduction: Whilst migraine treatment has advanced significantly over recent times, the mechanisms of attack genesis and heterogeneity in treatment response are two amidst several areas that remain poorly understood and require further development. Experimental migraine provocation is an area that holds promise in advancing this understanding.Areas covered: We conducted a literature search using PubMed, of 'human migraine triggering' and 'human migraine provocation' to identify articles of interest. We discuss therapeutic targets that have emerged from such work, including calcitonin family peptides (amylin (AMY) and adrenomedullin (ADM)), pituitary adenylate cyclase-activating peptide (PACAP) and potassium channels. We discuss our views on the clinical translation of the outcomes of such studies, and their previous and potential future impact on migraine therapeutics.Expert opinion: Migraine provocation models provide a valuable means to study human migraine phenotypically and biologically, as well as to assess treatment response. Downstream intracellular mechanisms of provocation agents can be targeted during cellular processing to alter cell function and influence migraine mechanisms. It is important to caveat the clinical translation of provocation studies, given that just because a substance triggers migraine experimentally, does not necessarily mean that the substance is involved in the spontaneous human condition.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0